Cerebral ischemia and neuroregeneration
| Autor: | Harlee E. Possoit, Hung Wen Lin, Celeste Y.C. Wu, Michelle H.H. Lee, Alexandre Couto e Silva, Alireza Minagar, Reggie Hui-Chao Lee, Tsung Han Hsieh |
|---|---|
| Rok vydání: | 2018 |
| Předmět: |
0301 basic medicine
medicine.medical_specialty Ischemia Resveratrol Tissue plasminogen activator Melatonin 03 medical and health sciences chemistry.chemical_compound 0302 clinical medicine Developmental Neuroscience Internal medicine medicine cardiovascular diseases Stroke business.industry Hypothermia Pifithrin medicine.disease Neuroregeneration 3. Good health 030104 developmental biology chemistry Cardiology medicine.symptom business 030217 neurology & neurosurgery medicine.drug |
| Zdroj: | Neural regeneration research. 13(3) |
| ISSN: | 1673-5374 |
| Popis: | Cerebral ischemia is one of the leading causes of morbidity and mortality worldwide. Although stroke (a form of cerebral ischemia)-related costs are expected to reach 240.67 billion dollars by 2030, options for treatment against cerebral ischemia/stroke are limited. All therapies except anti-thrombolytics (i.e., tissue plasminogen activator) and hypothermia have failed to reduce neuronal injury, neurological deficits, and mortality rates following cerebral ischemia, which suggests that development of novel therapies against stroke/cerebral ischemia are urgently needed. Here, we discuss the possible mechanism(s) underlying cerebral ischemia-induced brain injury, as well as current and future novel therapies (i.e., growth factors, nicotinamide adenine dinucleotide, melatonin, resveratrol, protein kinase C isozymes, pifithrin, hypothermia, fatty acids, sympathoplegic drugs, and stem cells) as it relates to cerebral ischemia. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|